Meeting
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
Authors
Anup Kasi
University of Kansas Cancer Center, Westwood, KS
Anup Kasi , Junqiang Dai , Raed Moh'd Taiseer Al-Rajabi , Joaquina Celebre Baranda , Anwaar Saeed , Prabhakar Chalise , Erin Carroll , Shannon Bradbury , Stephen Hyter , Malgorzata Anna Witek , Venkatadri Beeki , Richard J. McKittrick , Manidhar Reddy Lekkala , Anusha Chidharla , Sean Kumer , Timothy Schmitt , Stephen K. Williamson , Steven Soper , Andrew K. Godwin , Weijing Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03553004
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4156)
DOI
10.1200/JCO.2023.41.16_suppl.4156
Abstract #
4156
Poster Bd #
477
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.
First Author: Anup Kasi
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George